Status | Study |
RECRUITING |
Study Name: Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma Condition: Clear Cell Renal Cell Carcinoma Date: 2023-09-07 Interventions: Undergo blood and stool sample collection |
RECRUITING |
Study Name: A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors Condition: Clear Cell Renal Cell Carcinoma Date: 2023-03-21 Interventions: CTX131 (CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components) |
Completed |
Study Name: A Small-molecule Carbonic Anhydrase IX Targeting PET Tracer in Clear Cell Renal Cell Carcinoma Condition: Clear Cell Renal Cell Carcinoma Date: 2023-02-06 Interventions: Interventional |
Not yet recruiting |
Study Name: Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab Condition: Clear Cell Renal Cell Carcinoma Metastatic Renal Cell Carcinoma Date: 2017-05-04 Interventions: Drug: Nivolumab Nivolumab will |
Recruiting |
Study Name: PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma Condition: VHL Gene Mutation VHL VHL Syndrome Date: 2017-03-28 Interventions: Drug: PT2385 Tablets PT2385 inhibits HIF-2α and is a novel approach to treatment of VHL disease-ass |
Not yet recruiting |
Study Name: Study to Evaluate Efficacy and Safety of Sunitinib in Patients With Renal Cell Carcinoma Who Have Progressed to First-line Immunotherapy Treatment Condition: Clear Cell Renal Carcinoma Date: 2017-02-23 Interventions: Drug: Sunitinib Sunitinib 50 mg/d |
Recruiting |
Study Name: Addition of X4P-001 to Nivolumab Treatment in Patients With Renal Cell Carcinoma Condition: Clear Cell Renal Cell Carcinoma Date: 2016-09-30 Interventions: Drug: X4P-001 Continuous, oral |
Completed |
Study Name: Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma Condition: Metastatic Clear Cell Renal Cell Carcinoma Date: 2016-07-26 Interventions: Drug: Sunitinib |
Recruiting |
Study Name: Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma Condition: Metastatic Clear Cell Renal Cell Carcinoma Date: 2016-05-19 Interventions: Drug: Nivolumab Nivolumab IV, |
Recruiting |
Study Name: Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma Condition: Clear Cell Renal Cell Carcinoma Date: 2016-01-20 Interventions: Drug: X4P-001 Continuous, oral |